Abstract
tAim: In our pilot study, we used plasma samples as liquid biopsy to search for miRNA signatures in patientswith acute myeloid leukemia (AML) at diagnosis and in remission achieved after standard chemotherapybefore planned transplantation.Material and methods: We examined 10 plasma samples from healthy volunteers and 8 paired samplesfrom patients with AML at diagnosis and in remission using TaqMan MicroRNA Arrays. The results werevalidated using single-target qPCR reactions run in triplicates.Results: We selected 6 miRNAs with expressions significantly sensitive to therapy: miR-199b-5p, miR-301b, miR-326, miR-361-5p, miR-625 and miR-655.
All selected miRNAs were not or very weaklyexpressed in healthy individuals. They were abundant in plasma in patients at diagnosis but their levelsdecreased after chemotherapy.Conclusion: We detected a therapy sensitive miRNA signature in plasma of patients with AML.